Literature DB >> 9327699

Comparison of the degree of hemodynamic tolerance during intravenous infusion of nitroglycerin versus nicorandil in patients with congestive heart failure.

A I Larsen1, L Gøransson, T Aarsland, J F Tamby, K Dickstein.   

Abstract

BACKGROUND: Continuous exposure to organic nitrates is associated with substantial tachyphylaxis. This study compares the development of tolerance during continuous intravenous treatment with nitroglycerin versus nicorandil over a 24-hour period. METHODS AND
RESULTS: Twenty patients with congestive heart failure and pulmonary capillary wedge pressure (PCWP) > or = 18 mm Hg were randomly assigned to nitroglycerin or nicorandil in a double-blind, crossover study. Doses were titrated to obtain a reduction of PCWP of at least 30% and then maintained. The mean pretreatment PCWP for nitroglycerin was 25.4 +/- 6.7 mm Hg, decreasing to 19.0 +/- 6.8 mm Hg at 24 hours. The values for nicorandil were 24.3 +/- 6.3 mm Hg and 15.6 +/- 4.5 mm Hg, respectively. Between-treatment difference was significant (p < 0.01). The difference between the minimal PCWP value and the 24-hour PCWP value for nitroglycerin was 5.1 mm Hg vs 1.4 mm Hg for nicorandil (p < 0.005). The mean systemic vascular resistance was 1418 +/- 355 dynes.sec.cm-5 before nitroglycerin infusion, decreasing to 1312 +/- 353 dynes.sec.cm-5 at 24 hours. Corresponding values for nicorandil were 1420 +/- 366 dynes.sec.cm-5 and 967 +/- 274 dynes.sec.cm-5. Between-treatment difference was significant (p = 0.005). Tachyphylaxis developed in 12 (60%) patients during nitroglycerin infusion versus three patients (15%) during nicorandil infusion.
CONCLUSION: This study demonstrates that intravenous nicorandil administration results in significantly less hemodynamic tolerance over a 24-hour period compared with nitroglycerin. This finding may represent a clinical advantage for nicorandil in the short-term treatment of patients with congestive heart failure.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9327699     DOI: 10.1016/s0002-8703(97)70078-4

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  5 in total

1.  Vasodilators in Acute Heart Failure: Review of the Latest Studies.

Authors:  Phillip D Levy; Said Laribi; Alexandre Mebazaa
Journal:  Curr Emerg Hosp Med Rep       Date:  2014-06

Review 2.  Use of nicorandil in cardiovascular disease and its optimization.

Authors:  Shigeo Horinaka
Journal:  Drugs       Date:  2011-06-18       Impact factor: 9.546

Review 3.  Nicorandil. An updated review of its use in ischaemic heart disease with emphasis on its cardioprotective effects.

Authors:  A Markham; G L Plosker; K L Goa
Journal:  Drugs       Date:  2000-10       Impact factor: 9.546

Review 4.  Nicorandil: a review of its use in the management of stable angina pectoris, including high-risk patients.

Authors:  Dene Simpson; Keri Wellington
Journal:  Drugs       Date:  2004       Impact factor: 9.546

5.  Population pharmacokinetic and pharmacodynamic modelling of the effects of nicorandil in the treatment of acute heart failure.

Authors:  Satofumi Iida; Haruki Kinoshita; Nicholas H G Holford
Journal:  Br J Clin Pharmacol       Date:  2008-09       Impact factor: 4.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.